Skip to main content

Table 4 OS and PFS (all patients)

From: Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.

 

Median OS (months)

Median PFS (months)

Protein Expression

Low

High

P-value

Low

High

P-value

 ERCC1

21.4

10.5

0.006

10.2

5.1

0.027

 COX2

17.7

10.5

0.051

6.5

5.2

0.463

 Tubulin B3

11.6

11.9

0.704

6

6

0.347

 CD4

11.9

11.9

0.446

5.6

8.8

0.253

 CD8

13.5

8.6

0.041

6

3.9

0.766

SNPs

        

MDR1 C3435T

CC

TT

CT

P-value

CC

TT

CT

P-value

 

20.2

16.5

10.5

0.19

7.9

6.6

6

0.654

MDR1 G2677 T

GG

TT

GT

 

GG

TT

GT

 
 

8.6

3.6

17.7

0.119

5.1

2.9

8.6

0.027

ERCC1C8092A

AA

CC

CA

 

AA

CC

CA

 
 

25.2

11.6

15.4

0.756

2.8

6

6

0.543

ERCC1 N118 N

CC

TT

CT

 

CC

TT

CT

 
 

8.2

21.4

8.5

0.063

5.2

8.8

3.9

0.006